Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
Phase 1, single-center, randomized, placebo-controlled, double-blind clinical trial. Participants (N = 15) will receive a 2-dose schedule (1 vaccination on day 1 and day 28) randomized, receiving either MVA-BN-EBV (n = 12) or placebo (n = 3).
Epistemonikos ID: d07aa0951be0452ad754559eff6c725b0129b358
First added on: Oct 23, 2026